Pfizer to remain aggressive on obesity market after setback

Pfizer (PFE.N) will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.